Overview

• The Supreme Court dismissed a case challenging the FDA's approval of mifepristone due to lack of standing.
• Legal experts warn that the ruling does not address the merits of the case, leaving it vulnerable to future challenges.
• State legislatures and lower courts may continue to pose threats to medication abortion access.
• The Comstock Act remains a potential tool for restricting the distribution of abortion medications.
• Reproductive rights advocates emphasize the need for continued vigilance and legislative action.